EXTON, Pa., November 23, 2011 – Fibrocell Science, Inc. (OTCBB:FCSC.OB), an biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics and Metabolic Disorders Conference to be held on Tuesday, December 6, 2011 at the St. Regis Hotel in San Francisco.

Fibrocell’s presentation is scheduled for 3:40 p.m. Pacific Time.

The presentation will be webcast live, and a replay will be available on the Investors section of the Company’s website at www.fibrocellscience.com.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTCBB: FCSC) is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.

CONTACTS:

Media
Marina Maher Communications
Jessica Morrison
(212) 485-6806
jmorrison@mahercomm.com

Investors
ICR, LLC
Sherry Bertner
(646) 277-1247
sherry.bertner@icrinc.com